Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
about
S100β as a serum marker in endocrine resistant breast cancer.In vivo models in breast cancer research: progress, challenges and future directions.AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: A meta-analysis.Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma PropertiesPrecision medicine in breast cancer: reality or utopia?Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis.In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Breast cancer stem cell: the roles and therapeutic implications.Clonal cooperativity in heterogenous cancers.CTC clusters in cancer progression and metastasis.HER2 mRNA transcript quantitation in breast cancer.Extracellular pH is a biomarker enabling detection of breast cancer and liver cancer using CEST MRI.A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer.LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker.Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity.Imaging-guided revival of nanomedicine?Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution.Tumor Heterogeneity in Breast Cancer.Fatty acid synthase (FASN) as a therapeutic target in breast cancer.The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seqIntegrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancerNMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway
P2860
Q33556608-A5F31979-5773-4AEF-B2C1-44A9960E69ECQ33588117-F62D33F8-87B3-4EB9-BF64-3729EA08AB8AQ33667940-C726EF94-CCF4-4413-AB90-0CA7770FFE89Q33672809-BC89A80C-6DB9-40D8-92BE-E7CA882470EDQ33715750-9DF929B5-0FA9-4F88-AD07-7CCB8AC69A97Q33809114-69811FF3-A045-4EB8-9A11-4731C6A20DF7Q36090325-1480E302-07A9-4F1E-B3BF-031A34792810Q36962569-0A53003D-D0D5-4469-9296-28D0091EF47BQ37513954-4FABB8E8-C588-4C09-AD0B-2C363C3BC923Q38825960-E95E0855-728A-4D15-A617-C3C6881165DEQ38929036-7531510B-2021-4B07-9EC3-BCA4892A1147Q38943125-77FBABD2-57FD-451E-B41A-9C3757D48486Q39052331-FA33CAD2-ADB2-4BE6-99B7-610EED8BB1C2Q40419939-FAF7B028-F918-43C0-8A0E-3CD6520AE68FQ41233687-229F065B-C141-4576-B471-BE0C6CA4F753Q41662372-9500EE7C-4074-4F6E-9EC0-42ECC3DB932AQ42282812-B1123B15-AEE5-4C84-9910-7D6E263B46DAQ46670174-0351736F-35AE-4E9C-969B-1C5BDD9F7B50Q47110103-19F90A74-BFD8-4F74-A78B-501C5D95C722Q47115988-EBC75E27-DBD2-437F-92CA-AEA7E2DDC3A9Q47134627-17B21F92-7BF6-440D-B5A6-AC3612CFF266Q47146956-1D6C1CDE-656E-4048-AC0B-38CD965E225DQ50044384-A1649516-E8F1-44BB-A1C6-F85B94A51F1DQ52671376-9B40F672-AFE8-4661-A5F0-C479DA0537E2Q55388746-6A7B58AE-5E21-41A3-9D4D-CBEFAD29CDA8Q55397731-16BAF515-F230-4EE3-BD58-5C811B82B423Q58765307-1633B733-CBFE-4BC8-B505-A7ACDE8808E1Q58797844-8C77EB98-D059-43C1-A594-0E6F71ABD808Q59128928-A0DE703B-0CEC-4E6D-AE7D-F7E37A921AFA
P2860
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@ast
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@en
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@nl
type
label
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@ast
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@en
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@nl
prefLabel
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@ast
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@en
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@nl
P3181
P1433
P1476
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
@en
P2093
Mohamed Bentires-Alj
Shany Koren
P304
P3181
P356
10.1016/J.MOLCEL.2015.10.031
P407
P577
2015-11-19T00:00:00Z